Clinical Trial Update: Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing a Controlled Nitric Oxide Releasing Patch with Meglumine Antimoniate for cutaneous leishmaniasis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Leishmaniasis

Drugs mentioned

• Controlled Nitric Oxide Releasing Patch
• Meglumine antimoniate (meglumine antimoniate)

Snippet

Sponsor: Fundación Cardiovascular de Colombia | Conditions: Cutaneous Leishmaniasis | Phase 3 | Status: TERMINATED